Title:Paeonol Attenuates the Endothelial-to-Mesenchymal Transition Induced
by TGF-β1 in Human Umbilical Vein Endothelial Cells through ALK5-
Smad2/3 Signaling Pathway
Volume: 20
Issue: 1
Author(s): Yulong Yang, Yuning Liang, Xiaoyan Shi, Hongfei Wu, Yarong Liu, Tingting Jiang, Jinjin Yan, Min Zhou, Menglong Gao and Min Dai*
Affiliation:
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, 230012, China
- Anhui Key Laboratory for Research and Development of Traditional Chinese Medicine, Hefei, 230012, China
Keywords:
Paeonol, atherosclerosis, endothelial-to-mesenchymal transition, activin receptor-like kinase 5, human umbilical vein endothelial cells, transforming growth factor-β1.
Abstract:
Background: Paeonol (Pae), the main active compound of the root of Paeonia albiflora,
is efficacious in treating atherosclerosis (AS). Endothelial dysfunction is throughout the pathological
progression of AS. It is expected that inhibition of Endothelial-to-mesenchymal transition
(EndMT) will be a key target for AS treatment.
Objective: In this study, we investigated the molecular mechanism of the regulatory effect of Pae
on EndMT in human umbilical vein endothelial cells (HUVECs).
Methods: Cell cytotoxicity, proliferation, and migration were detected by CCK-8, the wound healing
assay, and EdU staining, respectively. The protein expressions were measured by Western blot
or immunofluorescence staining. Immunofluorescence staining was performed to indicate endothelial
cells undergoing EndMT in ApoE-/- mice. In vitro TGF-β1-induced EndMT assays were performed
in HUVECs and the effect of Pae was explored.
Results: We demonstrated that Pae could improve induced TGF-β1-EndMT in vivo and in vitro.
Mechanism study revealed that Pae directly bonds to the activin-like kinase 5 (ALK5, also known
as TGFβ type I receptor), inhibited downstream Smad2/3 phosphorylation, and thus alleviated
EndMT. Notably, overexpression of ALK5 significantly reversed the inhibitory effect of Pae on
EndMT in HUVECs.
Conclusion: Our results indicate that ALK5 is a promising druggable target for AS, and pharmacological
regulation of ALK5-Smad2/3 signaling pathway with small-molecule holds great potential
to benefit AS patients.